Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL ...
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire-AsiaNet/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical ...
Authors: LATEST ASIANET NEWS RELEASES